TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03892902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468
Description: Film-coated tablet for oral use at a dose strength of 50 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468
Description: Film-coated tablet for oral use at a dose strength of 50 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Description: Over-encapsulated to maintain blinding.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching to maintain blinding.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching to maintain blinding.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching to maintain blinding.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching to maintain blinding.
Study: NCT02609932

Intervention type: DRUG
Group type: OTHER
Intervention: Administration of drug (Interferon-gamma 1-b) subcutaneously
Description: SD = group who has received a single dose of IFN-gamma (10, 25, 50, and 100 mcg/m2) given once with subsequent analysis of effects (serum IL-10, Neuropterin, and IFN levels as well as neutrophil Nox2 activity and gene expression by Affimetrics Chip analysis). One month is allowed between doses. SS = administration of four doses (50 mcg/m2) of IFN-gamma given on Monday, Wednesday Friday schedule with neutrophil or monocyte function studies performed before the first and after the fourth dose to determine steady state effects.
Study: NCT03490539

Intervention type: DRUG
Intervention: Mycophenolate Mofetil
Description: oral tablets

Intervention type: DRUG
Intervention: Azathioprine
Description: oral tablet
Study: NCT03052374

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VID-KIDS Intervention Program
Description: Investigators created VID-KIDS for mothers with PPD to improve sensitivity and positive responsiveness towards their infants. Video-feedback has the advantage of being visually concrete yet distant because the action and the feedback are not concurrent; this helps mothers maintain an element of objectivity that may minimize guilty feelings associated with potential perceived lack of parenting skills. Video-feedback interventionists are trained by investigators with manualized modules. Including: Introduction to Video-feedback; NCAST Keys to Caregiving Program; Infant Engagement and Disengagement Cues; Video-feedback Intervention Protocol; Overview of Behaviours of Interest; Case Studies; and Examples of Strengths-Based Feedback. VID-KIDS intervention follows an 8-step protocol.
Study: NCT03330977

Intervention type: DEVICE
Group type: OTHER
Intervention: Compression garments
Description: Patients will wear the compression garments since 4 months after inclusion in order to have a comparison before and after use.~Usual practice would give to the patient the compression garments at inclusion.
Study: NCT04554225

Intervention type: DRUG
Intervention: Oxygen gas
Description: Oxygen administered to a patient using ambulatory oxygen
Study: NCT01904084

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Volar locked plating
Description: Operative treatment of distal radius fracture with volar locking plate

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hoffman external fixator
Description: Patients with distal radius fracture operated with Hoffman external fixator
Study: NCT03267316

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAN04
Description: A fully humanized monoclonal immunoglobulin G1 (IgG1) antibody (hmAb) in aqueous solution administered by i.v. infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAN04
Description: A fully humanized monoclonal immunoglobulin G1 (IgG1) antibody (hmAb) in aqueous solution administered by i.v. infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAN04
Description: A fully humanized monoclonal immunoglobulin G1 (IgG1) antibody (hmAb) in aqueous solution administered by i.v. infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAN04
Description: A fully humanized monoclonal immunoglobulin G1 (IgG1) antibody (hmAb) in aqueous solution administered by i.v. infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAN04
Description: A fully humanized monoclonal immunoglobulin G1 (IgG1) antibody (hmAb) in aqueous solution administered by i.v. infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAN04
Description: A fully humanized monoclonal immunoglobulin G1 (IgG1) antibody (hmAb) in aqueous solution administered by i.v. infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAN04
Description: A fully humanized monoclonal immunoglobulin G1 (IgG1) antibody (hmAb) in aqueous solution administered by i.v. infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAN04
Description: A fully humanized monoclonal immunoglobulin G1 (IgG1) antibody (hmAb) in aqueous solution administered by i.v. infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Standard of care treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Standard of care treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Standard of care treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Standard of care treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Standard of care treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Standard of care treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Standard of care treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Standard of care treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Standard of care treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Standard of care treatment
Study: NCT03486327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR55
Description: A novel targeted ultrasound contrast agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR55
Description: A novel targeted ultrasound contrast agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR55
Description: A novel targeted ultrasound contrast agent
Study: NCT01578018

Intervention type: OTHER
Group type: OTHER
Intervention: Measure DCAM levels in blood
Description: Measure DCAM levels in blood

Intervention type: OTHER
Group type: OTHER
Intervention: DCAM levels in blood
Description: DCAM levels in blood
Study: NCT03159000

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 1ml of 1/3 saline

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: lidocaine/bupivacaine
Description: 1ml of a 50% 2% lidocaine and 50% 0.5% bupivacaine
Study: NCT06039007

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 7-day Fasting-Mimicking Diet (7-DAY FMD)
Description: This medically-designed dietary kit supplies food for 7 days, with Day 1 providing 1100 kcal, while days 2 to 5 provide 800 kcal per day.
Study: NCT01009073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: ABT-263 is taken orally.~Note - The dose and schedule is variable based on Arm and subject to change based on the toxicities observed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: ABT-263 is taken orally.~Note - The dose and schedule is variable based on Arm and subject to change based on the toxicities observed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: ABT-263 is taken orally.~Note - The dose and schedule is variable based on Arm and subject to change based on the toxicities observed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: 150 mg of erlotinib is taken orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan (3-week schedule)
Description: 180 mg/m2 over 90 minutes, irinotecan will be given by intravenous infusion on Day 1 of each 21 day cycle.~Note - The dose and schedule is subject to change based on the toxicities observed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan (weekly schedule)
Description: 75 mg/m2 over 45 minutes, irinotecan will be given by intravenous infusion on Days 1 and 8 of each 21 day cycle.~Note - The dose and schedule is subject to change based on the toxicities observed.
Study: NCT02737072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2510924
Description: Administered SQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2510924
Description: Administered SQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2510924
Description: Administered SQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Administered IV
Study: NCT02816658

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Inguinal Hernia Repair
Description: Laparoscopic Inguinal Hernia Repair

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Robotic Inguinal Hernia Repair
Description: Robotic Inguinal Hernia Repair
Study: NCT04642131

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine supplementation
Description: Participants will wear standard insoles and ingest caffeine in liquid form (3mg/kg) with carbohydrates.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Personalized insoles
Description: Participants will wear personalized insoles and ingest a drink of carbohydrates without caffeine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control condition
Description: Participants will wear standard insoles and ingest a drink of carbohydrates without caffeine
Study: NCT01534429

Intervention type: PROCEDURE
Intervention: Quantitative Sensory Testing
Description: Quantitative Sensory Testing and Neurophysiologic Testing to be done Pre-operatively and at 3 and 6 months post-operatively.
Study: NCT02981667

Intervention type: OTHER
Intervention: Exercise intensity
Description: Participants were randomized to 1 or 2 exercise intensities, moderate or high (interval training).
Study: NCT00296192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine nasal spray
Description: Rotigotine- HCl 2.5mg/mL nasal spray, dosage per puff of 275µg per 110µg administered in up to 4 deliveries

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine nasal spray
Description: Rotigotine- HCl 2.5mg/mL nasal spray, dosage per puff of 275µg per 110µg administered in up to 4 deliveries

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine nasal spray
Description: Rotigotine- HCl 2.5mg/mL nasal spray, dosage per puff of 275µg per 110µg administered in up to 4 deliveries

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine nasal spray
Description: Rotigotine- HCl 2.5mg/mL nasal spray, dosage per puff of 275µg per 110µg administered in up to 4 deliveries

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo nasal spray 1, 2 3, and 4 puffs
Study: NCT01875419

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: Patients - tDCS arm: 1 mA current delivered for 20 minutes once a week for 8 weeks, immediately prior to CBT.~Patients - Sham arm: brief current change at the beginning (0 min) and end of each stimulation session (20 min) in order to mimic the effect of an actual stimulation, but no current delivered in between.
Study: NCT01281488

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic surgery
Description: Undergo standard approach robot-assisted laparoscopic partial nephrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic surgery
Description: Undergo standard approach robot-assisted laparoscopic partial nephrectomy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indocyanine green
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indocyanine green
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indocyanine green
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indocyanine green
Description: Given IV
Study: NCT01875419

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive Behavioural Therapy
Description: 8 sessions of one hour (once weekly) immediately after tDCS or sham stimulation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: 8 sessions of one hour (once weekly) immediately after tDCS or sham stimulation
Study: NCT00877799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR845
Description: CR845 (0.024 mg/kg) administered the day after surgery (Day 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR845
Description: CR845 (0.008 mg/kg) administered the day after surgery (Day 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR845
Description: CR845 (0.040 mg/kg) administered immediately after surgery (Day 0)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo administered the day after surgery (Day 1)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo administered immediately after surgery (Day 0)
Study: NCT01281488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indocyanine green
Description: Given IV
Study: NCT01981434

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video game based obesity education
Description: The intervention will be in the form of a videogame in which both parent and their children will participate. The game incorporates lessons from research on avatars (e.g., the Proteus Effect), and game dynamics to explore ways to increase healthy eating and exercise.
Study: NCT00739206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR97276A
Description: Dose based on body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR97276A
Description: Dose based on body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR97276A
Description: Dose based on body weight
Study: NCT01711034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPB-111077
Description: Dose escalation phase starting with dose of 100mg tablets on Day 1 and 4, and all remaining days of each 28 day cycle until disease progression or toxicity develops.~Dose expansion phase starting with daily dosing of 250mg for 28 day consecutive day cycles.
Study: NCT01158924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intradiscal rhGDF-5
Description: The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
Study: NCT04613609

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Cigarette containing nicotine
Description: Non-smokers used an electronic cigarette containing nicotine

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Electronic Cigarette without nicotine
Description: Non-smokers used an electronic cigarette without nicotine
Study: NCT01014507

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 8 cycles BEACOPPesc plus oral contraceptive

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8 cycles BEACOPPesc plus Goserelin
Study: NCT02857127

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking program
Description: To encourage people to exercise more through a behavioural and educational intervention during six months and other six months of follow up.
Study: NCT00562874

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meat Biscuit
Description: 75 women and one of their children will receive a biscuit containing dried meat as an ingredient for 5 days each week for 12 months. Women will receive 525 calories and 21 grams of protein per day and children will receive 350 calories and 14 grams of protein per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy Biscuit
Description: 75 women and one of their children will receive a biscuit containing soy four as an ingredient for 5 days each week for 12 months. Women will receive 525 calories and 21 grams of protein per day and children will receive 350 calories and 14 grams of protein per day.
Study: NCT00784446

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Oxaliplatin, Capecitabine, Bevacizumab, Imatinib
Description: Dose level I:~Bevacizumab day 1: 7,5 mg/kg body weight Oxaliplatin day 1: 100 mg/m2 Capecitabine days 1-14 bid: 800 mg/m2 Imatinib days 1-21: 300 mg~Repeat on day 22.~Dose level II:~Bevacizumab day 1: 7,5 mg/kg body weight Oxaliplatin day 1: 130 mg/m2 Capecitabine days 1-14 bid: 1000 mg/m2 Imatinib days 1-21: 300 mg~Repeat on day 22.
Study: NCT00902356

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AMG 167
Description: Subjects will be randomized to receive 1 of 5 doses of AMG 167 or equivalent volume of placebo administered as a single dose. Postmenopausal women will receive AMG 167 in fixed doses of 21 mg, 70, 210, 350, or 700 mg SC (under the skin), or 70 mg or 350 mg IV (in the vein), while men will receive doses of 70 mg or 350 mg SC or IV.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized to receive 1 of 5 doses of AMG 167 or equivalent volume of placebo administered as a single dose. Postmenopausal women will receive AMG 167 in fixed doses of 21 mg, 70, 210, 350, or 700 mg SC (under the skin), or 70 mg or 350 mg IV (in the vein), while men will receive doses of 70 mg or 350 mg SC or IV.
Study: NCT00934271

Intervention type: RADIATION
Intervention: fractionated stereotactic radiotherapy
Description: Audit of outcome
Study: NCT00724451

Intervention type: BIOLOGICAL
Intervention: Peginterferon alfa-2b
Description: Peginterferon alfa-2b administered in accordance with approved labeling

Intervention type: DRUG
Intervention: Ribavirin
Description: Ribavirin administered in accordance with approved labeling

Intervention type: BIOLOGICAL
Intervention: Peginterferon alfa-2a
Description: Peginterferon alfa-2a administered in accordance with approved labeling
Study: NCT00562874

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Wheat Biscuit
Description: 75 women and one of their children will receive a biscuit containing only wheat lour as a source of protein as an ingredient for 5 days each week for 12 months. Women will receive 525 calories and 8 grams of protein per day and children will receive 350 calories and 5 grams of protein per day.
Study: NCT01632800

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High pulsed magnetic fields
Description: Magnetic fields will escalate in strength
Study: NCT05337878

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pelacarsen-matching placebo administered by SC injection.
Study: NCT00136565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: 1.5 mg/m², D1, D5, 4 cycles
Study: NCT05337878

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pelacarsen-matching placebo administered by SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pelacarsen
Description: Pelacarsen administered by SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pelacarsen
Description: Pelacarsen administered by SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pelacarsen
Description: Pelacarsen administered by SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pelacarsen
Description: Pelacarsen administered by SC injection.
Study: NCT00136565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 75 mg/m², D1, 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 60 mg/m², D1-D5, 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 1200 mg/m², D1, 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vindesine
Description: 2 mg/m², D1, D5, 4 cycles
Study: NCT02651623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Multiple doses of sertraline for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: A single dose of 400 mg Moxifloxacin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Drug - Placebo
Description: Placebo administered for 14 days
Study: NCT03992690

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain-machine Interfaces, Visuo-tactile Feedback and Assisted Locomotion, or the WANR protocol
Description: Training integrating virtual-reality avatar driven by a brain-machine interface, with tactile feedback through patient's forearms, and assisted locomotion, for neurorehabilitation of SCI patients.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Training with traditional physiotherapy protocol
Description: Stretching
Study: NCT01470287

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTwP-HepB-Hib Vaccine
Description: Open label, Single arm study to evaluate immunogenicity, safety and tolerability of a fully liquid pentavalent (DTwP-HepB-Hib) vaccine in infants of 6-8 weeks of age.
Study: NCT00136565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: 10 mg, D1, D5, 4 cycles
Study: NCT04496765

Intervention type: PROCEDURE
Intervention: Total mesorectal excision
Description: Radical resection of rectal cancer and draining lymph nodes

Intervention type: PROCEDURE
Intervention: Total mesorectal excision
Description: Radical resection of rectal cancer and draining lymph nodes
Study: NCT01734226

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prunus Mume Extract
Description: Prunus Mume Extract (3.94g/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (3.94g/day)
Study: NCT01131481

Intervention type: DEVICE
Group type: OTHER
Intervention: Intraocular lens